Neutralization, effector function and immune imprinting of Omicron variants
Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots
in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on …
in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on …
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA. 2 and BA. 5 subvariant predominance: A systematic literature …
M Drysdale, M Berktas, DC Gibbons, C Rolland… - Infection, 2024 - Springer
Purpose To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a …
V Patel, MJ Yarwood, B Levick… - Current Medical …, 2024 - Taylor & Francis
Objective To describe characteristics and acute clinical outcomes for patients with COVID-19
treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated patients at highest …
treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated patients at highest …
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …
Intramuscular vs intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized noninferiority clinical trial
AE Shapiro, E Sarkis, J Acloque, A Free… - Open forum …, 2023 - academic.oup.com
Background Convenient administration of coronavirus disease 2019 (COVID-19) treatment
in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action …
in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action …
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
V Patel, B Levick, S Boult, DC Gibbons… - BMC Infectious …, 2024 - Springer
Background The impact of the constantly evolving severe acute respiratory syndrome
coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments …
coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments …
Safety, virology, pharmacokinetics, and clinical experience of high-dose intravenous sotrovimab for the treatment of mild to moderate COVID-19: an open-label clinical …
J Moya, M Temech, S Parra, E Juarez… - Open Forum …, 2023 - academic.oup.com
Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort …
M Drysdale, H Tibble, V Patel, DC Gibbons… - BMC Infectious …, 2024 - Springer
Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against
new circulating variants remains unclear. We sought to describe characteristics and clinical …
new circulating variants remains unclear. We sought to describe characteristics and clinical …
A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance
D Focosi - Viruses, 2023 - mdpi.com
Drug appropriateness is a pillar of modern evidence-based medicine, but the turnaround
times of genomic sequencing are not compatible with the urgent need to deliver treatments …
times of genomic sequencing are not compatible with the urgent need to deliver treatments …